Ebola Bundibugyo Vaccines in Development Four Months Before Outbreak
An Ebola outbreak in the Ituri province of the Democratic Republic of the Congo (DRC) was confirmed by the Africa Centers for Disease Control and Prevention (Africa CDC) on May 15, 2026. Through laboratory analysis, health officials confirmed that the outbreak is caused by the Bundibugyo ebola strain, for which there is no vaccine currently […]
Patients Request Blood from Donors Who Have Not Received mRNA COVID-19 Shots
A growing number of patients are requesting blood transfusions from donors who have not gotten the COVID19 shot, according to a Mar. 28, 2026 report published in the journal Transfusion. In the report, researchers at Vanderbilt Medical Center Medical Center evaluated 15 cases over a period of two years between 2024 and 2025 in which […]
Pfizer, BioNTech End mRNA COVID-19 Biologic Trial Early
After failing to recruit enough eligible volunteers to generate enough data in the U.S. to meet U.S. Food and Drug Administration (FDA) post-marketing evidence requirements, Pfizer, Inc. and BioNTech SE have halted a large clinical trial of their updated mRNA COVID-19 biologic. The study targeted healthy adults 50 to 64 years of age but fell […]
Moderna’s mNEXSPIKE mRNA COVID-19 Shot Approved by European Commission
The European Commission (EC) has granted marketing authorization for Moderna’s mNEXSPIKE mRNA COVID-19 shot, allowing it to be marketed across the European Union (U.N.). The authorization follows a regulatory review and permits all 27 E.U. Member States, as well as Iceland, Liechtenstein and Norway, to consider the shot for use within their vaccination programs. It […]
Combination mRNA COVID-Influenza Shot Recommended by European Medicines Agency
The European Medicine Agency (EDA) has recommended marketing authorization for Moderna’s mCombriax mRNA (messenger ribonucleic acid) shot. The product, also known as mRNA-1083, is a genetically engineered biologic targeting both influenza and COVID-19. It builds on work Moderna has done on its next-generation mRNA COVID shot known as mNexSpike and mRNA-1010.1 2 3 The recommendation […]
FDA Greenlights Review of Moderna’s mRNA Flu Shot After Application Amended
On Feb. 18, 2026, the U.S. Food and Drug Administration (FDA) agreed to review Moderna’s application for its mRNA influenza shot, known as mRNA-1010, after the company amended its submission to address regulatory concerns. The agency accepted the updated biologics license application and set a target action date of Aug. 5, 2026, allowing the shot […]